135 related articles for article (PubMed ID: 38875031)
21. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Economic Assessment in Early-Stage Dementia by Severity and Amyloid-β Status: A 5-Year Retrospective Claims Study of GERAS-US Patients.
Chandler J; Kubisiak J
J Alzheimers Dis; 2023; 91(2):753-765. PubMed ID: 36502319
[TBL] [Abstract][Full Text] [Related]
23. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
[TBL] [Abstract][Full Text] [Related]
24. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
[TBL] [Abstract][Full Text] [Related]
25. 2022 Alzheimer's disease facts and figures.
Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
[TBL] [Abstract][Full Text] [Related]
26. Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.
Wessels AM; Belger M; Johnston JA; Yu Y; Rentz DM; Dowsett SA; Chandler J
J Alzheimers Dis; 2022; 88(2):577-588. PubMed ID: 35694928
[TBL] [Abstract][Full Text] [Related]
27. Modelling the Pan-European Economic Burden of Alzheimer's Disease.
Martins R; Urbich M; Brännvall K; Gianinazzi M; Ching JE; Khoury CP; El-Hayek YH
JAR Life; 2022; 11():38-46. PubMed ID: 36923231
[TBL] [Abstract][Full Text] [Related]
28. Quality of Life and Caregiver Burden of Alzheimer's Disease Among Community Dwelling Patients in Europe: Variation by Disease Severity and Progression.
Froelich L; Lladó A; Khandker RK; Pedrós M; Black CM; Sánchez Díaz EJ; Chekani F; Ambegaonkar B
J Alzheimers Dis Rep; 2021; 5(1):791-804. PubMed ID: 34870105
[TBL] [Abstract][Full Text] [Related]
29. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
Belger M; Haro JM; Reed C; Happich M; Kahle-Wrobleski K; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
BMC Med Res Methodol; 2016 Jul; 16():83. PubMed ID: 27430559
[TBL] [Abstract][Full Text] [Related]
30. Health Care Resource Use and Social Costs in Mild Cognitive Impairment and Mild Alzheimer's Disease.
Takechi H; Yoshino H
J Alzheimers Dis Rep; 2023; 7(1):731-738. PubMed ID: 37483328
[TBL] [Abstract][Full Text] [Related]
31. Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.
Igarashi A; Azuma MK; Zhang Q; Ye W; Sardesai A; Folse H; Chavan A; Tomita K; Tahami Monfared AA
Neurol Ther; 2023 Aug; 12(4):1133-1157. PubMed ID: 37188886
[TBL] [Abstract][Full Text] [Related]
32. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
[TBL] [Abstract][Full Text] [Related]
33. Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions.
Wimo A; Handels R; Winblad B; Black CM; Johansson G; Salomonsson S; Eriksdotter M; Khandker RK
J Alzheimers Dis; 2020; 75(3):891-902. PubMed ID: 32390617
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.
Ito K; Chapman R; Pearson SD; Tafazzoli A; Yaffe K; Gurwitz JH
JAMA Netw Open; 2021 Oct; 4(10):e2129392. PubMed ID: 34677596
[TBL] [Abstract][Full Text] [Related]
35. The Humanistic and Economic Burden of Alzheimer's Disease.
Tahami Monfared AA; Byrnes MJ; White LA; Zhang Q
Neurol Ther; 2022 Jun; 11(2):525-551. PubMed ID: 35192176
[TBL] [Abstract][Full Text] [Related]
36. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
[TBL] [Abstract][Full Text] [Related]
37. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
[TBL] [Abstract][Full Text] [Related]
38. Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis.
Tariot PN; Boada M; Lanctôt KL; Hahn-Pedersen J; Dabbous F; Udayachalerm S; Raket LL; Halchenko Y; Michalak W; Weidner W; Cummings J
Alzheimers Res Ther; 2024 Feb; 16(1):36. PubMed ID: 38355706
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
